DeepMed Research

Statens Serum Institut

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: -

Established: 1902-01-01

Employees: -

Market Cap: -

Website: https://www.ssi.dk/

Clinical Trials

Safety Study Investigating if Concomitant Injections of C-Tb and 2 T.U Tuberculin Affect Induration Responses

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Biological: C-Tb
Biological: Tuberculin PPD RT 23 SSI
Biological: C-Tb / Tuberculin PPD RT 23 SSI

First Posted Date: 2013-01-30

Last Posted Date: 2015-04-17

Lead Sponsor: Statens Serum Institut

Target Recruit Count: 456

Registration Number: NCT01779102

Locations: 🇿🇦
TASK, M2, Karl Bremer Hospital,, Cape Town, South Africa
🇿🇦
Be Part Yoluntu Centre, Paarl, Western Cape, South Africa
🇿🇦
Tiervlei Trial Centre, Karl Bremer Hospital, Cape Town, South Africa

and more 4 locations

A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI

Phase 3

Completed

Conditions: Tuberculosis

Interventions: Biological: 2 T.U. Tuberculin PPD RT 23 SSI
Biological: C-Tb

First Posted Date: 2012-07-17

Last Posted Date: 2016-04-14

Lead Sponsor: Statens Serum Institut

Target Recruit Count: 1190

Registration Number: NCT01642888

Locations: 🇿🇦
Primecure Medicentre, Mercantile Hospital, Port Elizabeth, Eastern Cape, South Africa
🇿🇦
Worthwhile Clinical Trials, Lakeview Hospital, Benoni 1501, Gauteng, South Africa
🇿🇦
Setshaba Research Centre, Pretoria, Gauteng, South Africa

and more 6 locations

Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSI

Phase 3

Completed

Conditions: Tuberculosis

Interventions: Biological: C-Tb
Biological: 2 T.U. Tuberculin PPD RT 23 SSI

First Posted Date: 2012-06-29

Last Posted Date: 2015-04-17

Lead Sponsor: Statens Serum Institut

Target Recruit Count: 979

Registration Number: NCT01631266

Locations: 🇪🇸
Hospital Universitario de Cruces, Barakaldo, Basque Country, Spain
🇪🇸
Hospital Vall d'Hebron, Barcelona, Catalonia, Spain
🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain

and more 10 locations

Treatment Study of Metronidazole to Treat Dientamoebiasis in Children

Phase 4

Completed

Conditions: Dientamoebiasis

Interventions: Drug: Metronidazole
Drug: Placebo

First Posted Date: 2011-03-15

Last Posted Date: 2013-06-26

Lead Sponsor: Statens Serum Institut

Target Recruit Count: 100

Registration Number: NCT01314976

Locations: 🇩🇰
Statens Serum Institut, Copenhagen, Denmark

A Trial of the C-Tb Skin Test, When Given Intradermally to Healthy Volunteers Previously Vaccinated With BCG

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Biological: 2 TU Tuberculin PPD RT 23 SSI
Biological: C-Tb

First Posted Date: 2010-11-17

Last Posted Date: 2013-01-21

Lead Sponsor: Statens Serum Institut

Target Recruit Count: 151

Registration Number: NCT01242475

Locations: 🇬🇧
Surrey Clinical Research Centre, University of Surrey, Surrey, Guildford, Surrey, United Kingdom

A Trial of the C-Tb Skin Test, When Given Intradermally to Adult Patients Recently Diagnosed With Active Tuberculosis (TB)

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Biological: C-Tb
Biological: 2 TU Tuberculin PPD RT 23 SSI

First Posted Date: 2010-11-16

Last Posted Date: 2015-04-17

Lead Sponsor: Statens Serum Institut

Target Recruit Count: 253

Registration Number: NCT01241188

Locations: 🇿🇦
University of Cape Town Lung Institute (Pty) Ltd, Cape Town, South Africa

HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease

Phase 1

Completed

Conditions: Aids, Cdc Group I

Interventions: Biological: AFO-18
Drug: Saline

First Posted Date: 2010-06-10

Last Posted Date: 2013-08-08

Lead Sponsor: Statens Serum Institut

Target Recruit Count: 18

Registration Number: NCT01141205

Locations: 🇬🇼
Hospital Nacional Simao Mendes, Bissau, Guinea-Bissau

A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Biological: Antigen (Ag85B-ESAT-6)
Biological: Antigen (Ag85B-ESAT-6) with adjuvant (IC31)

First Posted Date: 2010-01-14

Last Posted Date: 2015-04-17

Lead Sponsor: Statens Serum Institut

Target Recruit Count: 39

Registration Number: NCT01049282

A Safety and Dose Finding Trial of C-Tb, When Given to Adult Patients Recently Diagnosed With Active Tuberculosis

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Biological: rdESAT-6 + rCFP-10 (C-Tb)

First Posted Date: 2009-12-17

Last Posted Date: 2013-01-21

Lead Sponsor: Statens Serum Institut

Target Recruit Count: 38

Registration Number: NCT01033929

Locations: 🇬🇧
St George's University of London, London, London SW17 0RE, United Kingdom

Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults

Phase 3

Completed

Conditions: Healthy

Interventions: Biological: TdaP vaccine SSI
Biological: Td vaccine SSI

First Posted Date: 2009-12-17

Last Posted Date: 2013-01-21

Lead Sponsor: Statens Serum Institut

Target Recruit Count: 802

Registration Number: NCT01033877

Locations: 🇩🇰
H:S Rigshospitalet, Copenhagen, Denmark
🇩🇰
aCROnordic, Hoersholm, Denmark

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy